Roan Capital Partners’s Merck MRK Stock Holding History

Roan Capital Partners’s Portfolio MRK Stock Details MRK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$426K	Sell	3,318 -93	-3%	-$10.9K	0.35%	47
2026 Q1	$410K	Buy	+3,411	New	+$394K	0.38%	47

Other funds holding MRK

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Roan Capital Partners's MRK Position: Q2 2026 in Review

Roan Capital Partners reduced its Merck (MRK) stake by 2.7% in Q2 2026, selling an estimated $10.9K and leaving 3,318 shares worth $426K. The position accounts for 0.35% of the portfolio, ranked #47.

Roan Capital Partners first reported a position in MRK in Q1 2026 and has held it in 2 quarters since. 3,814 funds tracked by Wall St. Rank hold MRK as of Q2 2026.

Roan Capital Partners held 3,318 shares of Merck worth $426K as of Q2 2026.
Roan Capital Partners sold 93 Merck shares in Q2 2026, an estimated $10.9K.
Merck made up 0.35% of Roan Capital Partners's portfolio in Q2 2026, its #47 holding.
Roan Capital Partners first reported a position in Merck in Q1 2026 and has held it in 2 quarters since.
3,814 funds tracked by Wall St. Rank held Merck as of Q2 2026.

Based on Roan Capital Partners's 13F filing for Q2 2026, filed 9 Jul 2026.